10 completed, 1 recruiting, 1 withdrawn. 12 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 10, Recruiting 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 2, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Hypophosphatasia: new trials by email Literature Review of Hypophosphatasia trials Research Report on Hypophosphatasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ALE1 in Healthy Adults and Adults With Hypophosphatasia in Order to Identify Suitable Doses of ALE1 ALE1, Placebo - Hypophosphatasia (HPP) | Phase 1 / Phase 2 | Recruiting | Alesta Therapeutics | 120 | 2025-09-30 | 2026-08-03 |
| Pilot Trial of Single Dose Ilofotase Alfa in Hypophosphatasia Ilofotase Alfa, 0.8 mg/kg, Ilofotase Alfa, 3.2 mg/kg - Hypophosphatasia | Phase 1 / Phase 2 | Completed | AM-Pharma | 12 | 2023-05-15 | 2025-02-27 |
| Pharmacokinetic and Dose Response Study of Asfotase Alfa in Adult Patients With Pediatric-Onset Hypophosphatasia (HPP) Asfotase alfa - Hypophosphatasia | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 27 | 2016-06-06 | 2019-09-17 |
| Safety and Efficacy of Asfotase Alfa in Patients With Hypophosphatasia (HPP) Asfotase Alfa (ALXN1215) - Hypophosphatasia | Phase 2 | Completed | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan | 13 | 2014-08-01 | 2016-03-31 |
| Dose Escalation Study to Evaluate the Safety and Tolerability of Multiple Infusions of BPS804 in Adults With Hypophosphatasia (HPP) BPS804 - Hypophosphatasia | Phase 2 | Completed | Ultragenyx Pharmaceutical Inc | 8 | 2011-07-01 | 2022-09-16 |
| Open-Label Study of Asfotase Alfa in Infants and Children ≤ 5 Years of Age With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia | Phase 2 / Phase 3 | Completed | Alexion Pharmaceuticals, Inc. | 69 | 2010-07-01 | 2019-03-13 |
| Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 19 | 2010-06-01 | 2019-03-13 |
| Extension Study of Protocol ENB-006-09 - Study of Asfotase Alfa in Children With Hypophosphatasia (HPP) Asfotase Alfa - Hypophosphatasia (HPP) | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 12 | 2010-04-01 | 2019-03-13 |
| Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia (HPP) | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2009-09-01 | 2019-04-01 |
| Safety and Efficacy Study of ENB-0040 in Juvenile Patients With Hypophosphatasia (HPP) ENB-0040 - Hypophosphatasia | Phase 2 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2009-07-01 | 2023-08-04 | |
| Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia | Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 10 | 2009-04-01 | 2019-03-13 |
| Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP) asfotase alfa - Hypophosphatasia (HPP) | Phase 1 / Phase 2 | Completed | Alexion Pharmaceuticals, Inc. | 11 | 2008-09-01 | 2019-04-01 |
Osteomalacia (7) · Rickets (7) · Bone Diseases (6)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (12) · Genetic Diseases, Inborn (12) · Metabolic Diseases (12) · Metabolism, Inborn Errors (12) · Metal Metabolism, Inborn Errors (12) · Nutritional and Metabolic Diseases (12) · Avitaminosis (7) · Bone Diseases, Metabolic (7) · Calcium Metabolism Disorders (7) · Deficiency Diseases (7) · Malnutrition (7) · Musculoskeletal Diseases (7) · Nutrition Disorders (7) · Vitamin D Deficiency (7) · Bone Diseases (1)
asfotase alfa (9) · setrusumab (1)
Alexion Pharmaceuticals, Inc. (8) · AM-Pharma (1) · Alesta Therapeutics (1) · Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan (1) · Ultragenyx Pharmaceutical Inc (1)
United States (7) · Canada (5) · Germany (5) · United Kingdom (4) · Japan (2) · United Arab Emirates (2) · Australia (1) · France (1) · Italy (1) · New Zealand (1) · Russia (1) · Saudi Arabia (1) · Spain (1) · Turkey (Türkiye) (1)
Keiichi Ozono (1) · Michael P. Whyte, MD (1)
PMID 26529632, PMID 32417537, PMID 32762706, PMID 27699270, PMID 22397652, PMID 28436937, PMID 30558909, PMID 30811537, PMID 30969260, PMID 32987199, PMID 33822385, PMID 41378916